Cardiovascular disease: risk assessment and reduction, including lipid modification

of lipid-lowering treatment for secondary prevention of CVD. Assessing response to treatment See the section on assessing response to treatment. 1.8 Statins for primary and secondary prevention of cardiovascular disease in people with chronic kidney disease See NICE's guideline on chronic kidney disease for CKD classification. People on renal replacement therapy are outside the scope of this guideline. 1.8.1 Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD. [May 2023] 1.8.2 If the lipid target for primary or secondary prevention of CVD (see recommendation 1.6.1 and recommendation 1.7.1) is not met and eGFR is 30 ml per minute per 1.73 m2 or more, increase the dose of atorvastatin. [May 2023, amended December 2023] 1.8.3 Agree the use of higher doses with a renal specialist if eGFR is less than 30 ml per minute per 1.73 m2. [May 2023] Optimising statin treatment See the section on optimising statin treatment. Assessing response to treatment See the section on assessing response to treatment. 1.9 Optimising statin treatment 1.9.1 If the lipid target for primary or secondary prevention of CVD (see recommendation 1.6.1 and recommendation 1.7.1) is not met: â€¢ discuss adherence and timing of statin dose
